TY - JOUR
T1 - Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection
AU - Tokuhara, Daisuke
AU - Álvarez, Beatriz
AU - Mejima, Mio
AU - Hiroiwa, Tomoko
AU - Takahashi, Yuko
AU - Kurokawa, Shiho
AU - Kuroda, Masaharu
AU - Oyama, Masaaki
AU - Kozuka-Hata, Hiroko
AU - Nochi, Tomonori
AU - Sagara, Hiroshi
AU - Aladin, Farah
AU - Marcotte, Harold
AU - Frenken, Leon G.J.
AU - Iturriza-Gómara, Miren
AU - Kiyono, Hiroshi
AU - Hammarström, Lennart
AU - Yuki, Yoshikazu
PY - 2013/9/3
Y1 - 2013/9/3
N2 - Rotavirus-induced diarrhea is a life-threatening disease in immunocompromised individuals and in children in developing countries. We have developed a system for prophylaxis and therapy against rotavirus disease using transgenic rice expressing the neutralizing variable domain of a rotavirus-specific llama heavy-chain antibody fragment (MucoRice-ARP1). MucoRice-ARP1 was produced at high levels in rice seeds using an overexpression system and RNAi technology to suppress the production of major rice endogenous storage proteins. Orally administered MucoRice-ARP1 markedly decreased the viral load in immunocompetent and immunodeficient mice. The antibody retained in vitro neutralizing activity after long-term storage (>1 yr) and boiling and conferred protection in mice even after heat treatment at 94°C for 30 minutes. High-yield, watersoluble, and purification-free MucoRice-ARP1 thus forms the basis for orally administered prophylaxis and therapy against rotavirus infections.
AB - Rotavirus-induced diarrhea is a life-threatening disease in immunocompromised individuals and in children in developing countries. We have developed a system for prophylaxis and therapy against rotavirus disease using transgenic rice expressing the neutralizing variable domain of a rotavirus-specific llama heavy-chain antibody fragment (MucoRice-ARP1). MucoRice-ARP1 was produced at high levels in rice seeds using an overexpression system and RNAi technology to suppress the production of major rice endogenous storage proteins. Orally administered MucoRice-ARP1 markedly decreased the viral load in immunocompetent and immunodeficient mice. The antibody retained in vitro neutralizing activity after long-term storage (>1 yr) and boiling and conferred protection in mice even after heat treatment at 94°C for 30 minutes. High-yield, watersoluble, and purification-free MucoRice-ARP1 thus forms the basis for orally administered prophylaxis and therapy against rotavirus infections.
UR - http://www.scopus.com/inward/record.url?scp=84883532793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883532793&partnerID=8YFLogxK
U2 - 10.1172/JCI70266
DO - 10.1172/JCI70266
M3 - Article
C2 - 23925294
AN - SCOPUS:84883532793
VL - 123
SP - 3829
EP - 3838
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
SN - 0021-9738
IS - 9
ER -